BackgroundKnee osteoarthritis (KOA) is one of the most prevalent degenerative diseases that cause pain and disability. None of the currently available treatments reverses or heals the degenerative nature of this condition. There were many research studies on the efficacy of PRP therapy in early KOA patients. However, there was no clinical study on its extraction or administration in a COVID-19 patient with KOA.Hence, the main objective of this observational study was to analyse the implication of COVID-19 infection on PRP extraction along with Red Blood Cell Distribution Width (RDW) and platelet count levels. Methods & FindingsWe present a case report of knee osteoarthritis administered with two ultrasound-guided Platelet-Rich Plasma (PRP) injections pre and post covid-19 infection. As the patient was affected with COVID-19 infection immediately after a week of the first PRP session, he was finally administered the second dose only after 21 days, followed by the third final dose after 6 weeks.
Background: COVID-19 disease has gained much attention across the globe due to its quick transmission with a high mortality rate. Although research studies are ongoing to determine the best treatment, vaccination turned out to be the most promising preventive measure against SARS-CoV-2. Currently, four COVID-19 vaccines are approved and used across the world. However, people undergoing regenerative treatment were doubtful whether it worked after the vaccination. In this study, we assessed the safety of the regenerative treatment in patients with knee osteoarthritis (KOA) post-COVID-19 vaccination. Methods: 131 knee joints of patients aged between 45 to 85 years with KOA, grade 3-4 of the Kellgren-Lawrence scale, who received vaccination against COVID-19, were randomly administered with BMAC, Lipogem, PRP, and GOLDIC treatments. For 12 months, these patients were evaluated for side effects. Results: During 12 months of follow-up, 90% of the patients experienced no side effects. Only 7% reported minor side effects like headache and sore arms to post COVID-19 vaccination. Conclusion:Regenerative treatment was safe in patients with moderate-to-severe KOA for 12 months post-COVID-19 vaccination.
Menopause is a natural, gradual transition between active and inactive ovarian functions that last several years in women's lives and involves changes in both the body and the mind. Women enter an estrogen-deficient phase during menopause, which speeds up the ageing process. They are more likely to develop osteoarthritis compared to men, and the prevalence of the condition rises dramatically during menopause for women. As a result, this article aims to understand the connection between menopause and osteoarthritis, followed by various strategies for managing arthritis symptoms in postmenopausal women.
Background: Knee osteoarthritis is the most common musculoskeletal progressive disorder that affects nearly 303 million people worldwide. This condition prevails in 10% males and 13% females among the elders above 60. Although there is conventional nonsurgical and surgical treatment available for knee osteoarthritis, there is a fascinating interest in bone marrow aspirate concentrate (BMAC) as well as adipose-derived mesenchymal stem cells (AD-MSC), including enzymatically treated stromal vascular fraction (SVF) and mechanically treated (microfat/nanofat) injections among physicians. Hence, this systematic review aims to determine the efficacy of BMAC and AD-MSCs (enzyme and mechanically treated) injections for knee osteoarthritis treatment. Methods: A systematic review was performed on the following data sources (PubMed, Scopus, Google Scholar, EMBASE, and Cochrane Library) published on March 31, 2021. The keywords or MeSH terms include 'Knee Osteoarthritis with 'Bone marrow aspirate concentrate' OR 'BMAC' or with 'Adipose-derived mesenchymal stem cells (AD-MSC)' or with 'Stromal vascular fraction' OR 'SVF' or 'Mechanically treated AD-MSC (mfat/nanofat)'. In addition, the retrieved articles were further reviewed to identify relevant research studies. Results: The authors reviewed and tabulated data based on the year of study, study type, therapy protocol, patient population, outcome measures, and interpretation. Among the 382 records screened, 43 studies (16 on BMAC and 27 on AD-MSCs) were included in the systematic review study. Among them, only 5 were randomized controlled trials. These selected studies demonstrated short-term positive outcomes such as improvement in knee pain and function with no adverse side effects. Moreover, researchers reported varied administration methods of BMAC or AD-MSC either as standalone or in combination with other conservative procedures such as PRP (Platelets Rich Plasma), HA (Hyaluronic acid), or surgery. Conclusions: BMAC and AD-MSC (enzymatically and mechanically treated) injections prove safer and more efficacious in patients with knee osteoarthritis for a shorter duration of 2 years. However, the available literature lacks high-quality studies with no varied clinical settings and long-term follow-up of more than two years.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.